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Transferrin (Tf) is the serum protein responsible for deliv-ering iron to the erythron and peripheral tissues. Tf takesup iron derived from dietary absorption and from
macrophage recycling and delivers it to utilizing cells that inter-
nalize the Tf-bound iron through transferrin receptor 1 (TfR1).1
A second transferrin receptor exists, TfR2, which binds the
iron-loaded Tf with a lower affinity than TfR1.2 TfR2 has a reg-
ulatory function in the liver and in the erythroid compart-
ment.3,4 Under physiological conditions, almost all iron in the
circulation is bound to Tf. However, in diseases resulting in
iron overload, Tf is saturated with iron, and excess iron is pres-
ent in the plasma as non-Tf-bound iron (NTBI). The exact route
of uptake of NTBI remains unclear, but it is well established
that NTBI is responsible for parenchymal cell iron overload.1,5
β-thalassemia is a congenital anemia characterized by inef-
fective erythropoiesis, increased Tf saturation and tissue iron
overload.6 It represents a paradigmatic disorder of erythro-
poiesis characterized by anemia and dysfunction of iron home-
ostasis. In 2010, Li and co-authors reported that administration
of exogenous apoTf to β-thalassemic mice ameliorated anemia.
Specifically, apoTf injections normalized red blood cell survival
and increased hemoglobin production and concomitantly
decreased reticulocytosis, erythropoietin abundance and
splenomegaly. Moreover, Tf treatment normalized plasma
NTBI and increased hepcidin expression.7
In this issue of Haematologica, Gelderman, Baek and co-
authors extended those results and reported that apoTf may be
used to reverse hemochromatosis in β-thalassemia.8 In a differ-
ent mouse model of β-thalassemia intermedia (Hbbth3/+), they
confirmed that chronic apoTf administration normalizes ane-
mia. Furthermore, they demonstrated normalization of tissue
iron content in the liver, kidney and heart. ApoTf treatment
was also found to attenuate transfusion-mediated increases in
plasma NTBI and tissue iron. These therapeutic effects were
associated with normalization of Tf saturation and suppressed
plasma NTBI. 
The positive effect of apoTf treatment on erythropoiesis is
due to restriction of erythropoiesis resulting from reduced iron
uptake. The expansion of the plasma Tf pool decreases the
amount of diferric-Tf in favor of monoferric-Tf, which has a
lower affinity for TfR1. This is expected to reduce iron avail-
ability for heme synthesis and consequently limit α-globin
aggregates and hemichrome formation thus ameliorating inef-
fective erythropoiesis. Similar results were obtained in β-tha-
lassemic mice placed on a low-iron diet or engineered to over-
express hepcidin to limit iron availability.9 Furthermore, admin-
istration of apoTf to hypotransferrinemic mice, which suffered
from an iron-restricted anemia associated with tissue iron over-
load, corrected anemia by improving iron delivery to erythroid
cells.10 These results clearly indicate that the plasma Tf pool
controls iron delivery to the erythron thus representing a limit-
ing factor in regulating erythropoiesis in mice. 
The second positive effect of the Tf therapy in β-thalassemic
mice is a reduction of tissue iron accumulation. Tissue iron
overload represents an important risk for β-thalassemic
patients, especially for transfusion-dependent ones. In fact,
despite chelation therapy, myocardial disease remains the life-
limiting complication of secondary iron overload in thalassemic
patients.6 Reduction of tissue iron in apoTf-treated β-tha-
lassemic mice is achieved through two main mechanisms,
reduction of NTBI and normalization of hepcidin level. Plasma
NTBI increases when Tf is fully saturated and is responsible for
iron accumulation in parenchymal tissues. Expansion of the
plasma Tf pool reduces NTBI and consequently iron uptake by
tissues. In this context, exogenous Tf represents a natural iron
chelator. Concomitantly, Tf supplementation, by correcting
anemia, normalizes hepcidin level. Hepcidin is the master reg-
ulator of iron metabolism. Hepcidin is a liver hormone and reg-
ulates iron absorption and iron recycling by controlling the
plasma membrane expression of the iron exporter ferroportin.
Hepcidin is regulated by iron, hypoxia, inflammation and ery-
thropoiesis.11 Interestingly, holoTf regulates hepcidin expres-
sion through TfR2 and the hemochromatosis gene HFE. Holo-
Tf binds both TfR1 and TfR2, although it has a stronger affinity
for TfR1. In a proposed model, HFE associates with TfR1 under
low iron conditions and is displaced when TfR1 binds holoTf.
As serum iron and holoTf concentrations rise, the ratio of TfR2
to TfR1 expression increases. Together, this leads to
TfR2/holoTf membrane stabilization and induces HFE/TfR2
binding and hepcidin expression.12 Nevertheless, in the context
of stress erythropoiesis, such as in β-thalassemia, hepcidin is
suppressed despite high Tf saturation, due to the dominant
effect of the erythroid regulator. The latter senses the erythro-
poietic requirement for iron and signals to the liver to reduce
hepcidin expression. Recently, erythroferrone, a hormone pro-
duced by erythroblasts in response to erythropoietin has been
demonstrated to be the erythroid regulator, at least in condi-
tions of stress erythropoiesis.13 When erythropoiesis is stimu-
lated, erythroferrone is induced and this results in suppression
of hepcidin expression and increased iron availability for the
erythroid compartment. Data from Gelderman, Baek and co-
authors support this role since they found that normalization
of anemia due to apoTf treatment was associated with sup-
pression of erythroferrone expression and an increase of hep-
cidin level that, as expected, resulted in reduced ferroportin in
the gut.8 It is likely that normalization of anemia reduces ery-
thropoietin level and attenuates erythropoietin receptor signal-
ing including erythroferrone expression. Interestingly, TfR2
was shown to act as an iron sensor on erythroid cells.14,15 TfR2
is associated with erythropoietin receptor on erythroblasts and
negatively regulates their sensitivity to erythropoietin.
Moreover, it has been reported that holoTf stabilizes TfR2 at
the plasma membrane while in conditions of iron deficiency
(low Tf saturation) TfR2 is shed from the plasma membrane
and a soluble form is released.16 According to the model of Nai
et al., shedding of TfR2 from the plasma membrane of ery-
throid cells results in increased erythropoietin sensitivity, high
erythroferrone and low hepcidin.14
Thus, the plasma Tf pool controls iron accumulation in tis-
sues and iron delivery to the erythroid compartment and con-
comitantly regulates hepcidin expression through TfR2 (Figure
1). In iron deficiency, holoTf is reduced and this results in the
shedding of TfR2, which, on hepatocytes reduces
TfR2/HFE signaling on hepcidin promoter and on erythrob-
lasts promotes erythropoietin signaling and erythroferrone
expression. In conditions of iron overload with normal
(effective) erythropoiesis, holoTf is increased and this stabi-
lizes TfR2 on hepatocytes, inducing hepcidin, and on ery-
throblasts, limiting erythropoietin sensitivity, maybe to
avoid excessive red blood cell production. When erythro-
poiesis is ineffective, the regulatory role of Tf/TfR2 is over-
ridden by the hyperactivation of erythropoietin signaling
which suppresses hepcidin leading to abnormal expansion
of the plasma iron pool. Supplementation with exogenous
Tf reduces NTBI avoiding tissue iron loading, and normal-
izes anemia thus reducing erythropoietin signaling and
restoring normal iron-Tf control of hepcidin expression
(Figure 1). 
Another interesting observation from the work of
Gelderman, Baek and co-authors is the lack of effect of hap-
toglobin and hemopexin in reducing hemochromatosis in
β-thalassemic mice.8 Haptoglobin and hemopexin are plas-
ma proteins that bind hemoglobin and heme, respectively,
with high affinity. In hemolytic conditions, when hemoglo-
bin and heme are released into the bloodstream, haptoglo-
bin and hemopexin mediate hemoglobin and heme recov-
ery by hepatocytes and macrophages, respectively, thus
promoting heme iron recycling and preventing heme from
having toxic effects.17 Administration of hemopexin to a dif-
ferent mouse model of β-thalassemia (Hbbth1/th1) was shown
to be effective in preserving vascular homeostasis by pro-
moting heme iron recovery by the liver.18 Gelderman, Baek
and co-authors showed that hemopexin as well as hapto-
globin supplementation does not alter plasma iron levels or
tissue iron loading.8 This indicates that in the Hbbth3/+mouse
model the rate of intravascular hemolysis does not con-
tribute significantly to hemochromatosis. Nevertheless, in
pathological conditions associated with a higher rate of
hemolysis, such as in sickle cell disease, or under a chronic
transfusion regimen, the supplementation of hemoglobin
and heme scavengers might be beneficial.19
In conclusion, it is time to speculate that the modulation
of plasma protein pools represents a valuable therapeutic
approach to control iron delivery to bone marrow and
parenchymal tissues. Increasing serum Tf, with serum puri-
fied or recombinant protein, may be useful not only in β-
thalassemia but in all pathological conditions characterized
by ineffective erythropoiesis.
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Figure 1. In physiological conditions,
plasma Tf limits iron accumulation
in parenchymal tissues and acts as
a signal sensed by the hepatocyte
and the erythroblast for regulating
hepcidin expression and iron avail-
ability. In pathological conditions
characterized by ineffective erythro-
poiesis, such as β-thalassemia, the
erythropoietin/erythropoietin recep-
tor hyperactivation causes an abnor-
mal expansion of erythropoiesis and
of plasma and tissue iron.
Supplementation with Tf normalizes
erythropoiesis and restores normal
iron sensing. The intensity of the
color of TfR2 or EpoR indicates the
state of stabilization/activation. See
text for details. Erfe: erythroferrone.
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There is currently a great deal of excitement regard-ing the role of stem cell niches that regulatehematopoietic stem cell self-renewal and differen-
tiation. It should be noted, however, that the original
description of a hematopoietic niche actually occurred in
1958 when the French hematologist, Marcel Bessis,
described erythroblastic islands.1 The island was charac-
terized by developing erythroblasts surrounding a central
macrophage and, based on careful structural observa-
tions, Bessis and colleagues made a number of interesting
inferences about the role of central macrophages in ery-
thropoiesis. It was suggested that the macrophage func-
tions as a “nurse” cell, providing iron to developing ery-
throblasts for heme synthesis and, furthermore, that the
extruded nuclei produced at the end of erythroid differen-
tiation are phagocytized by these central macrophages.2
These concepts proved prescient as they have been sup-
ported by a number of recent findings which have shown
that the macrophage-erythroblast interactions mediated
by a large number of adhesion molecules are essential for
the highly regulated process of erythroblast proliferation
and survival which is necessary for the production of two
million reticulocytes per second.3-6 In this context the
recent findings that in vivo depletion of erythroblastic
island macrophages blocks erythroblast proliferation and
maturation fully validates the central role of macrophages
in regulating erythropoiesis.7
Apart from playing an important role in the genesis of
red blood cells within the bone marrow, macrophages of
the reticulocyte endothelial system in general and spleen
in particular play a critical role in quality control by
removing senescent and damaged red cells from the circu-
lation.8-10 Thus different macrophage subsets play a dual
role in both the production of red cells and in the elimina-
tion of senescent normal red cells and pathological red
cells. This important symbiotic interrelationship between
erythroid and macrophage biology is receiving increasing
attention in hematology research since the findings of the
studies have direct relevance to our understanding of both
normal and disordered erythropoiesis. 
In this issue of Haematologica, Fraser and colleagues
describe exciting new findings regarding a key role for
heme-oxygenase-1 in both regulating erythroid differenti-
ation and in mediating clearance of circulating red cells
through its effect on macrophages.11 The work of Fraser et
al. documents that heme-oxygenase-1 deficiency adverse-
ly affects steady-state erythropoiesis in murine bone mar-
row due to a diminished ability of erythroblasts to form
erythroblastic islands. The reduction in erythroblastic
islands was the result of decreased numbers of the sub-
type of bone marrow macrophages involved in island for-
mation. These observations reinforce the concept of an
essential requirement of a specific subset of macrophages
for the formation of bone marrow erythroblastic islands
and that island formation is necessary to sustain normal
bone marrow erythropoiesis. Interestingly, the decreased
erythropoiesis in the bone marrow led to increased ery-
thropoiesis in the spleen, a common compensatory
response in the murine system in which the spleen is the
major erythropoietic organ that responds to stress ery-
thropoiesis. 
While heme-oxygenase-1 deficiency had a negative
effect on bone marrow erythropoiesis, it had a positive
effect on red cell life span in circulation as a result of com-
promised ability of the macrophages of the reticuloen-
dothelial system to remove senescent red cells. It thus
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